AzTrials
AzTrials

Rheumatoid ArthritisPhase 3OSKIRA - 2NCT01197534

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

A Phase 3 study testing fostamatinib in people with Rheumatoid Arthritis, run by AstraZeneca at 149 sites in 16 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
fostamatinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
913 participants
Where
149 sitesin 16 countries
Study dates
Sep 2010to Mar 2013
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Active rheumatoid arthritis (RA) diagnosed after the age of 16
  • Treatment with one the following disease modifying anti-rheumatic drug: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine
  • 4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count)and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more
  • At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)

Who cannot join

  • Females who are pregnant or breast feeding
  • Poorly controlled hypertension
  • Liver disease or significant liver function test abnormalities
  • Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders
  • Recent or significant cardiovascular disease
  • Significant active or recent infection including tuberculosis
Show all 9Show fewer
  • Previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment with other biological agent
  • Severe renal impairment
  • Neutropenia

Trial locations and contacts

149 sites in 16 countries.

149 sites in 16 countries

United States57 sites
  • Research Site

    Amarillo, Texas

  • Research Site

    Austin, Texas

  • Research Site

    Birmingham, Alabama

  • Research Site

    Boca Raton, Florida

  • Research Site

    Boise, Idaho

  • Research Site

    Brandon, Florida

  • Research Site

    Brooklyn, New York

  • Research Site

    Canton, Georgia

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Chesapeake, Virginia

  • Research Site

    Crofton, Maryland

  • Research Site

    Cumberland, Maryland

  • Research Site

    Dallas, Texas

  • Research Site

    Dayton, Ohio

  • Research Site

    Decatur, Georgia

  • Research Site

    Duncansville, Pennsylvania

  • Research Site

    Durham, North Carolina

  • Research Site

    Elizabethtown, Kentucky

  • Research Site

    Flowood, Mississippi

  • Research Site

    Glendale, Arizona

  • Research Site

    Greenville, South Carolina

  • Research Site

    Hagerstown, Maryland

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Houston, Texas

  • Research Site

    Huntington Beach, California

  • Research Site

    Jacksonville, Florida

  • Research Site

    Kalamazoo, Michigan

  • Research Site

    Kalispell, Montana

  • Research Site

    Las Cruces, New Mexico

  • Research Site

    Lubbock, Texas

  • Research Site

    Macon, Georgia

  • Research Site

    Manalapan, New Jersey

  • Research Site

    Memphis, Tennessee

  • Research Site

    Mesa, Arizona

  • Research Site

    Mesquite, Texas

  • Research Site

    Miami, Florida

  • Research Site

    Omaha, Nebraska

  • Research Site

    Orangeburg, South Carolina

  • Research Site

    Orlando, Florida

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Phoenix, Arizona

  • Research Site

    Rochester, New York

  • Research Site

    Roslyn, New York

  • Research Site

    San Antonio, Texas

  • Research Site

    Scottsdale, Arizona

  • Research Site

    South Bend, Indiana

  • Research Site

    St Louis, Missouri

  • Research Site

    Syracuse, New York

  • Research Site

    Tacoma, Washington

  • Research Site

    Tampa, Florida

  • Research Site

    Torrance, California

  • Research Site

    Trumbull, Connecticut

  • Research Site

    Tucson, Arizona

  • Research Site

    Venice, Florida

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    West Reading, Pennsylvania

  • Research Site

    Zephyrhills, Florida

Other trials in United States

Canada11 sites
  • Research Site

    Bowmanville, Ontario

  • Research Site

    Edmonton, Alberta

  • Research Site

    Hamilton, Ontario

  • Research Site

    Mississauga, Ontario

  • Research Site

    Montreal, Quebec

  • Research Site

    Ottawa, Ontario

  • Research Site

    Québec, Quebec

  • Research Site

    Reading

  • Research Site

    Toronto, Ontario

  • Research Site

    Trois-Rivières, Quebec

  • Research Site

    Winnipeg, Manitoba

Other trials in Canada

Czechia11 sites
  • Research Site

    Brno

  • Research Site

    Bruntál

  • Research Site

    Česká Lípa

  • Research Site

    České Budějovice

  • Research Site

    Hlučín

  • Research Site

    Liberec

  • Research Site

    Ostrava - Trebovice

  • Research Site

    Prague

  • Research Site

    Sokolov

  • Research Site

    Terezín

  • Research Site

    Zlín

Other trials in Czechia

India11 sites
  • Research Site

    Ahmedabad, Gujarat

  • Research Site

    Bangalore, Karnataka

  • Research Site

    Coimbatore, Tamil Nadu

  • Research Site

    Gandhinagar, Gujarat

  • Research Site

    Hyderabad, Andhra Pradesh

  • Research Site

    Lucknow

  • Research Site

    Madurai, Tamil Nadu

  • Research Site

    Mangalore, Karnataka

  • Research Site

    Mumbai, Maharashtra

  • Research Site

    Pune, Maharashtra

  • Research Site

    Vadodara, Gujarat

Other trials in India

United Kingdom9 sites
  • Research Site

    Basingstoke

  • Research Site

    Cambridge

  • Research Site

    Eastbourne, Sussex

  • Research Site

    London

  • Research Site

    Maidstone, Kent

  • Research Site

    Newcastle upon Tyne

  • Research Site

    Solihull, West Midlands

  • Research Site

    Stoke-on-Trent

  • Research Site

    Swindon

Other trials in United Kingdom

Israel8 sites
  • Research Site

    Ashkelon

  • Research Site

    Beer Yaakov

  • Research Site

    Haifa

  • Research Site

    Kfar Saba

  • Research Site

    Petah Tikva

  • Research Site

    Ramat Gan

  • Research Site

    Rehovot

  • Research Site

    Tel Aviv

Other trials in Israel

Ukraine8 sites
  • Research Site

    Kharkiv

  • Research Site

    Kyiv

  • Research Site

    Lutsk

  • Research Site

    Lviv

  • Research Site

    Simferopol

  • Research Site

    Vinnytsia

  • Research Site

    Zaporizhzhya

  • Research Site

    Zaporyzhzhya

Other trials in Ukraine

South Africa6 sites
  • Research Site

    Cape Town, W Cape

  • Research Site

    Durban, Kz-natal

  • Research Site

    Kempron Park, Gauteng

  • Research Site

    Port Elizabeth

  • Research Site

    Pretoria, Gauteng

  • Research Site

    Stellenbosch

Other trials in South Africa

Italy4 sites
  • Research Site

    Iesi, AN

  • Research Site

    Legnano, MI

  • Research Site

    Udine, UD

  • Research Site

    Varese, VA

Other trials in Italy

Romania4 sites
  • Research Site

    Baia Mare

  • Research Site

    Brailari

  • Research Site

    Bucharest

  • Research Site

    Ploieşti

Other trials in Romania

Serbia4 sites
  • Research Site

    Belgrade

  • Research Site

    Kragujevac

  • Research Site

    Niška Banja

  • Research Site

    Novi Sad

Other trials in Serbia

Spain4 sites
  • Research Site

    Barcelona

  • Research Site

    Getafe

  • Research Site

    La Laguna (tenerife), Canary Islands

  • Research Site

    Mérida, Extremadura

Other trials in Spain

Germany3 sites
  • Research Site

    Erlangen

  • Research Site

    Hamburg

  • Research Site

    München

Other trials in Germany

Latvia3 sites
  • Research Site

    Liepāja

  • Research Site

    Riga

  • Research Site

    Valmiera

Other trials in Latvia

Lithuania3 sites
  • Research Site

    Kaunas

  • Research Site

    Klaipėda

  • Research Site

    Šiauliai

Other trials in Lithuania

Portugal3 sites
  • Research Site

    Aveiro

  • Research Site

    Lisbon

  • Research Site

    Porto

Other trials in Portugal

About this study

Official title: (OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs

The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.

Read the detailed description

Sub-study:

Full title: Optional Genetic Research

Date: 18 June 2010

Version: 1

Objectives: To collect and store, with appropriate consent ,DNA samples for future exploratory research into genes/genetic variation that may influence response (ie, absorption, distribution, metabolism and excretion, safety, tolerability and efficacy) to fostamatinib disodium and/or methotrexate; and/or susceptibility to, progression of and prognosis of RA

Being tested
fostamatinib, placebo, fostamatinib
Keywords
Rheumatoid Arthritis
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • fostamatinibDrug

    fostamatinib 100 mg twice daily

  • fostamatinibDrug

    fostamatinib 100 mg twice daily/ 150 mg once daily

  • placebo, fostamatinibDrug

    Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.

Study groups in NCT01197534
Study groupRoleWhat they receive
Dosing Regimen AExperimentalOral Treatment
Receives: Drug: fostamatinib
Dosing Regimen BExperimentalOral Treatment
Receives: Drug: fostamatinib
Dosing Regimen CPlacebo comparatorOral Treatment
Receives: Drug: placebo, fostamatinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo

    ACR20: American College of Rheumatology 20% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: 24 weeks

Secondary outcomes (11)
  1. Proportion of Patients Achieving ACR20, Comparison Between Fostamatinib and Placebo at Week 1

    ACR20: American College of Rheumatology 20% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: 1 week

  2. Proportion of Patients Achieving ACR50, Comparison Between Fostamatinib and Placebo at Week 24

    ACR50: American College of Rheumatology 50% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: 24 weeks

  3. Proportion of Patients Achieving ACR70, Comparison Between Fostamatinib and Placebo at Week 24

    ACR70: American College of Rheumatology 70% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: 24 weeks

  4. ACRn - Comparison Between Fostamatinib and Placebo at Week 24

    ACRn: American College of Rheumatology index of RA improvement, based on smallest percentage improvement in the count of swollen joints (out of 28 joints), count of tender joints (out of 28 joints), or in blood test measures of inflammation (such as CRP) or the physician or patient's own assessments of disease activity, pain and physical function. Scores are reported as a percentage improvement on a scale of -100 to +100, with larger values representing a better clinical outcome. BID = twice daily, CI = confidence interval, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, PO = orally, QD = once a day. Mean refers to change at Week 24.

    Measured: Baseline and 24 weeks

  5. Proportion of Patients Achieving DAS28-CRP <2.6 at Week 12, Comparison Between Fostamatinib and Placebo

    DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. A DAS28-CRP score of <2.6 is indicative of remission of RA symptoms. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.

    Measured: 12 weeks

  6. Proportion of Patients Achieving DAS28-CRP <2.6 at Week 24, Comparison Between Fostamatinib and Placebo

    DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. A DAS28-CRP score of <2.6 is indicative of remission of RA symptoms. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, OR=odds ratio, PO = orally, QD=once a day.

    Measured: 24 weeks

  7. Proportion of Patients Achieving DAS28 EULAR Response at Week 24

    Change in DAS28 was derived for each post baseline scheduled assessment and categorised using the European League Against Rheumatism (EULAR) response criteria. BID = twice daily, DAS28 = Disease Activity Score based on a 28-joint count, DMARD = disease-modifying anti-rheumatic drug, OR=odds ratio, PO = orally, QD = once a day.

    Measured: 24 weeks

  8. HAQ-DI Response - Comparison of the Change(>=0.22) From Baseline Between Fostamatinib and Placebo at Week 24

    HAQ-DI: Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is then calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygiene, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. The HAQ-DI response is a reduction from baseline in HAQ-DI score greater than or equal to the minimally important difference (0.22). BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.

    Measured: Baseline and 24 weeks

  9. Change From Baseline to Week 24 in mTSS, Comparison Between Fostamatinib and Placebo

    mTSS: modified total sharp score, a measure of structural progression based upon X-rays. Hand and foot joints are scored for erosions and joint space narrowing and the results summed to give a value between 0 and 448. A higher value represents more serious progression of the disease. After disregarding ineligible records, patients with 2 or more non-missing values have had missing data imputed via linear extrapolation/interpolation methods. Patients with only 1 result were excluded from the analysis. ANCOVA = analysis of covariance, BID = twice daily, IP = investigational product, QD = once a day.

    Measured: Baseline and 24 weeks

  10. SF-36 - Comparison of the Change in PCS From Baseline Between Fostamatinib and Placebo at Week 24

    SF-36: 36-item Short Form Health Survey, a measure of health related quality of life. Scores for 8 sub-domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Function, Role-Emotional and Mental Health) are derived and normalised to a scale of 0-100. Physical and mental component scores (PCS and MCS) are derived by multiplying each of these 8 scores by a constant, summing them and standardising against a population with mean of 50+/- 10. Higher scores represent a better quality of life. Mean changes from baseline score are presented as increases from baseline (defined as post-baseline minus baseline); larger changes indicate a better clinical condition. ANCOVA = analysis of covariance, BID = twice daily, DMARD = disease modifying antirheumatic drugs, PO = orally, QD = once a day.

    Measured: Baseline and 24 weeks

  11. SF-36 - Comparison of the Change in MCS From Baseline Between Fostamatinib and Placebo at Week 24

    SF-36: 36-item Short Form Health Survey, a measure of health related quality of life. Scores for 8 sub-domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Function, Role-Emotional and Mental Health) are derived and normalised to a scale of 0-100. Physical and mental component scores (PCS and MCS) are derived by multiplying each of these 8 scores by a constant, summing them and standardising against a population with mean of 50+/- 10. Higher scores represent a better quality of life. Mean changes from baseline score are presented as increases from baseline (defined as post-baseline minus baseline); larger changes indicate a better clinical condition. ANCOVA = analysis of covariance, BID = twice daily, DMARD = disease modifying antirheumatic drugs, PO = orally, QD = once a day.

    Measured: Baseline and 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Sep 2010 (estimated)
  2. Study startSep 2010
  3. Primary completionMar 2013
  4. Study completionMar 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
913 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01197534
Sponsor's protocol ID
D4300C00002
Other IDs
2010-020744-35
Acronym
OSKIRA - 2
Status last verified
Mar 2014
First submitted
8 Sep 2010
Last updated
17 Apr 2014
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing fostamatinib in people with Rheumatoid Arthritis, run by AstraZeneca at 149 sites in 16 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 149 sites in United States, Canada, Czechia, India, United Kingdom and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Apr 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo (time frame: 24 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in